Basis of antihistamines use in atopic dermatitis



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Histamin as allergic mediator that plays a role in allergic reactions and may contribute to impairment of atopic dermatitis. But antihistamines does not always lead to significant improvement of clinical symptoms of atopic dermatitis. In this review we discuss therapeutic options for the treatment with antihistamines in patients with atopic dermatitis.

About the authors

D Sh Macharadze

D Sh Macharadze

References

  1. Charlesworth E., Massey W., Kagey-Sobotka A. et al. Effect of H1 receptor blockade on the early and late response to cutaneous allergen challenge. J. Pharmacol. Exp. Ther., 1992, v. 262, p. 964-970.
  2. Ring J. Plasma histamine concentrations in atopic eczema. Clin. Allergy, 1983, v. 13, p. 545-552.
  3. Leung D. Atopic dermatitis: new insights and opportunities for therapeutic intervention. J. Allergy Clin. Invest., 2000, v. 105, p. 860-876.
  4. Sicherer S.H. Food hypersensitivity and atopic dermatitis: Pathophysiology, epidemiology, diagnosis, and management. J. Allergy Clin. Immunol., 1999, v. 104 (3), p. 114-122.
  5. Mihm M., Soter N., Dvorak H., Austen K. The structure of normal skin and the morphology of atopic eczema. J. Invest. Dermatol., 1976, v. 67, p. 305-312.
  6. Ellis C., Luger T., Abeck D. et al. Новые клинические данные и современные стратегии лечения атопического дерматита. Аллергология, 2003, v. 4, p. 50-58.
  7. Koblenzer C. Itching and the atopic skin. J. Allergy Clin. Immunol., 1999, v. 104 (Suppl), S. 109-113.
  8. Wahlgren C., Tengvall Linder M., Hagermark O. et al. Itch and inflammation induced by intradermally injected interleukin-2 in atopic dermatitis patients and healthy subjects. Arch. Dermatol. Res., 1995, v. 287, p. 572-580.
  9. Rukwied R., Heyer G. Administration of acetylcholine and vasoactive intestinal polypeptide to atopic eczema patients. Exp. Dermatol., 1999, v. 8, p. 39-45.
  10. Nassif A., Chan S., Storrs G., Hanifin J. Abnormal skin irritancy in atopic dermatitis and in atopy without dermatitis. Arch. Dermatol., 1994, v. 130, p. 1402-1407.
  11. Pinselli C., Fantini F. , Massimi P. et al. Neuropeptide in skin from patients with atopic dermatitis: an immunohistochemical study. Br. J. Dermatol., 1990, v. 122, p. 745-750.
  12. Steinhoff M., Bienenstock J., Schmelz M. Neurophysiological, neuroimmunological, and neuroendocrine basis of pruritus. J. Invest. Dermatol., 2006, v. 126, p. 1705-1718.
  13. Klein P. , Clark R. An evidence-based review of the efficacy of antihistamines in relieving pruritis in atopic dermatitis. Arch. Dermatol., 1999, v. 135, p. 1522-1525.
  14. Hoare C., Li Wan Po A., Williams H. Systematic review of treatments of atopic dermatitis. Health Technol Assess 2000, v. 4, p. 1-191.
  15. Walsh G. The clinical relevance of the anti-inflammatory properties of antihistamines. Allergy 2000, v. 55, p. 53-61.
  16. Wahn U., ETAC Study Group. Allergic factors associated with the development of asthma and the influence of cetirizine in a double-blind, randomised, placebo-controlled trial: First results of ETAC. Pediatr. Allergy Immunol., 1998, v. 9, p. 116-124.
  17. Simons E., Silver N., Gu X., Simons K. Clinical pharmacology of H1-antihistamines in the skin. J. Allergy Clin. Immunol., 2002, v. 110, p. 777-783.
  18. Rihoux J.-P., Ghys L., Coulie P. Compared peripheral inhibiting effects of cetirizine 2HCl and loratadine. Ann. Allergy, 1990, v. 17, p. 139-142.
  19. Ramboer I., Bumbagea R., Lazarescu D., Radu J. Cetirizine and loratadine: a comparison using the ED50 in skin reactions. J. Int. Med. Res., 2000, v. 28, p. 69-77.
  20. Purohit A., Duvernelle C., Melac M. et al. Twenty-four hours of activity of cetirizine and fexofenadine in the skin. Ann. Allergy Asthma Immunol., 2001, v. 86, p. 387-392.
  21. Simons F., McMillan J., Simons K. A double-blind, single-dose, crossover comparison of cetirizine, terfenadine, loratadine, astemizole, and chlorpheniramine versus placebo: suppressive effects on histamine-induced wheals and flares during 24 hours in normal subjects. J. Allergy Сlin. Immunol., 1990, v. 86, p. 540-547.
  22. Fadel R., Herpin-Richard N., Dufresne F., Rihoux J.-P. Pharmacological modulation by cetirizine and loratadine of antigen and histamine-induced skin weals and flares, and late accumulation of eosinophils. J. Int. Med. Res. 1990, v. 18, p. 366-371.
  23. Charlesworth E., Kagey-Sobotka A., Norman R., Lichtenstein L. Effect of cetirizine on mast cell-mediator release and cellulat traffic during the cutaneous late-phase reaction. J. Allergy Clin. Immunol., 1989, v. 83, p. 905-912.
  24. Redier H., Chanez P. , De Vos C. et al. Inhibitory effect of cetirizine on the bronchial eosinophil recruitment induced by allergen inhalation challenge in allergic patients with asthma. Ibid, 1992, v. 9, p. 215-224.
  25. Juhlin L., Pihl-Lundin I. Effects of antihistamines on cutaneous reactions and influx of eosinophils after local injection of PAF, kallikrein, compound 48/80 and histamine in patients with chronic urticaria and healthy subjects. Acta, Derm. Veneorol., 1992, v. 72, p. 197-200.
  26. Henoco E., Vargaftig B. Skin eosinophillia in atopic patients. J. Allergy Clin. Immunol., 1988, v. 81, p. 691-695.
  27. Gaga M., Frew A., Varney V. et al. Eosinophil activation and T lymphocyte infiltration in allergen-induced late phase skin reactions and classical delayed type hypersensitivity. J. Immunol., 1991, v. 147, p. 816-822.
  28. Sehmi R., Walsh G., Hartnell A. et al. Modulation of human eosinophil chemotaxis and adhesion by antiallergic drugs in vitro. Pediatr. Allergy Immunol., 1993, v, 4 (Suppl 4), p. 13-18.
  29. Wittmann M., Kienlin P. Downregulation of co-stimulatory molecules on lymphocytes and decreased lymphocyte proliferation by fexofenadine. Allergy, 2001, v. 56 (Suppl 68), 128 (Abstr.).
  30. Berth-Jones J., Graham-Brown R. Failure of terfenadine in relieving the pruritis of atopic eczema. Br. J. Dermatol., 1989, v. 121, p. 635-637.
  31. Leurs R., Church M., Taglialatela M. H1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. Clin. Еxper. Allergy, 2002, v. 32, p. 489-498.
  32. Church M. H1-antihistamines and inflammation. Ibid, 2001, v. 31, p. 1341-1343.
  33. Ревякина В.А. Лечение сезонного и хронического ринита. Аллергия, астма и клин. иммунол., 1998, № 9, с. 10-32.
  34. Baker A., Johnson D., Levisky J. et al. Fatal diphenhydramine intoxication in infants. J. Forensic Sci., 2003, v. 48, p. 425-458.
  35. Winder J., Noonan M., Lumry W., Pearlman D. Absence of QТ prolongation with cetirizine in children aged 6 to 11 years. Ped. Asthma Allergy Immunol., 1996, v. 10, p. 181-190.
  36. Watson W., Simons K., Chen X., Simons F. Cetirizine: a pharmacokinetic and pharmacodynamic evaluation in children with seasonal allergic rhinitis. J. Allergy Clin. Immunol., 1989, v. 84, p. 457-464.
  37. Nicolas J., Whomsley R., Collart P. et al. In vitro inhibition of human liver drug metabolizing enzymes by second generation antihistamines. Chem. Biol. Interact., 1999, v. 123, p. 63-79.
  38. Дж. Бернстайн. Антигистаминные препараты. В кн.: Аллергические болезни. Диагностика и лечение. Под ред. Р. Паттерсон и соавт. «ГЭОТАР МЕДИЦИНА». М., 2000, с. 74-93.
  39. Доказательная медицина. Ежегодный справочник. М., «Медиа Сфера», 2002, 1400 с.
  40. Warner J. et al. A double-blind, randomized, placebo-controlled trial of cetirizine in preventing the onset of asthma in children with atopic dermatitis: 18 months treatment and 18 months posttreatment follow-up. J. Allergy Clin. Immunol., 2001, v. 108, p. 929-937.
  41. Simmons F. Prevention of acute urticaria in young children with atopic dermatitis. Ibid 2001, v. 107, p. 703-706.
  42. ETAC Study Group. Allergic factors associated with the development of asthma and the influence of cetirizine in a double-blind, randomised, placeb-controlled trial: first results of ETAC. Ped. Allergy Immunol., 1998, v. 9, p. 116-124.
  43. Bergmann R., Edenharter G., Bergmann K. et al. Atopic dermatitis in early infancy predicts allergic airway disease at 5 years. Clin. Exp. Allergy, 1998, v. 28, p. 965-970.
  44. Warner J. Correspondence. Publication bias with cetirizine in atopic dermatitis: safe but ineffective? J. Allergy Clin. Immunol., 2002, v. 110, p. 818.
  45. La Rosa M., Ranno C., Musarra I. et al. Double-blind study of cetirizine in atopic eczema in children. Ann. Allergy, 1994, v. 73, p. 117-122.
  46. Chunharas A., Wisuthsarewong W., Wananukul S., Viravan S. Therapeutic efficacy and safety of loratadine syrup in childhood atopic dermatitis treated with mometasone furoate 0.1 per cent cream. J. Med. Assoc. Thai., 2002, v. 85, p. 482-427.
  47. Welch M., Meltzer E., Simons F. H1-antihistamines and the central nervous system. In: Simons F. editor. Histamine and H1-antihistamines in allergic disease. 2nd ed. New York: Marcel Dekker, 2002, р. 337-88.
  48. Hannuksela M., Kalimo K., Lammintausta K. et al. Dose ranging study: cetirizine in the treatment of atopic dermatitis in adults. Ann. Allergy, 1993, v. 70, p. 127-133.
  49. Herman S., Vender R. Antihistamines in the treatment of atopic dermatitis. J. Cutan Med. Surg., 2003, v. 12, p. 27-29.
  50. Kawashima M., Tango T. , Noguchi T. et al. Addition of fexofenadine to a topical corticosteroid reduces the pruritis associated with atopic dermatitis in a 1-week randomized multicentre, double-blind, placebo-controlled, parallel-group study. Br. J. Dermatol., 2003, v. 148, p. 1212-1221.
  51. Kawakami T. , Kaminishi K., Soma Y. et al. Oral antihistamine therapy influences plasma tryptase levels in an adult atopic dermatitis. J. Dermatol. Sci., 2006, v. 43, p. 127-134.
  52. Niide M., Okubo J., Irisawa R., Tsuboi R. Clinical effects of olopatadine hydrochloride on pruritis in skin diseases. Arerugi, 2006, v. 55, p. 1327-1336.
  53. Макарова И.В., Разумовская Т.Н. Фексофенадина гидрохлорид (Телфаст) в лечении аллергических заболеваний у детей. Вопросы современной педиатрии, 2003, № 2, p. 91-94.
  54. Атопический дерматит у детей: диагностика, лечение и профилактика. М., 2000, 75 с.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright © Pharmarus Print Media, 2007



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies